CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
Rhea-AI Summary
CytoSorbents (NASDAQ: CTSO) announced a virtual fireside chat on December 15, 2025 where CEO Dr. Phillip Chan and CFO Peter J. Mariani will join D. Boral Capital to discuss recent company developments.
Key points highlighted include $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for DrugSorb-ATR with an FDA decision expected in mid-2026. The session will expand on Q3 results and near-term milestones shaping the company’s growth trajectory.
Event time: 11:00 AM – 12:00 PM EST, Dec 15, 2025. Registration via D. Boral Capital.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Down
CTSO was up 3.51% with light volume while scanner data flagged only WOK in momentum, down 20.83% without news. Other medical device peers (ELUT, SRTS, TELA, MDAI) showed modest gains but no broad, synchronized move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 17 | Conference participation | Neutral | -0.6% | Jefferies London conference presentation and one‑on‑one investor meetings. |
| Nov 13 | Earnings update | Positive | +4.2% | Q3 2025 results with revenue growth, strong margins, and restructuring plan. |
| Nov 11 | Conference participation | Neutral | -3.3% | Announcement of management attendance at Jefferies Global Healthcare Conference. |
| Oct 30 | Earnings scheduling | Neutral | +0.0% | Notice of upcoming Q3 2025 earnings release and investor call. |
| Sep 29 | Clinical data preview | Positive | -0.9% | Planned presentations of CytoSorb and DrugSorb‑ATR cardiac surgery data at EACTS. |
Recent CTSO news, mostly conferences and updates, has produced modest single‑digit price moves with no consistent pattern of large post‑headline dislocations.
Over the last few months, CytoSorbents has focused on investor outreach and clinical visibility. It highlighted new cardiac surgery data at EACTS in early Oct 2025, then scheduled and reported Q3 2025 results, delivering $9.5M in revenue and a 70% gross margin while narrowing losses. Multiple conference appearances in Nov 2025 extended this outreach. The new fireside chat builds directly on the Q3 call, emphasizing $37.0M in trailing 12‑month sales and ongoing FDA progress for DrugSorb‑ATR toward an expected mid‑2026 decision.
Market Pulse Summary
This announcement underscores CytoSorbents’ focus on investor engagement following its Q3 2025 earnings, where it reported $9.5M in revenue, a 70% gross margin, and ongoing losses. Management aims to elaborate on trailing $37.0M in high‑margin sales, a strengthened balance sheet, and regulatory progress toward an expected mid‑2026 FDA decision for DrugSorb‑ATR. Investors may watch upcoming regulatory milestones, cash trends, and any strategic updates shared during the December 15 fireside chat.
Key Terms
fda regulatory
AI-generated analysis. Not financial advice.
Fireside Chat Details:
Title: Transforming Critical Care: CytoSorbents' Blood-Purification Programs Deliver Growing Revenues as DrugSorb-ATR Moves Toward a Mid-2026 FDA Review
Date: Monday, December 15, 2025
Time: 11:00 AM – 12:00 PM EST
Registration: D. Boral Capital – CytoSorbents
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine storm and cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.
CytoSorbents' lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide, with nearly 300,000 devices used cumulatively to date. CytoSorb was originally launched in the European Union under CE mark as the first cytokine adsorber. Additional CE mark extensions were granted for bilirubin and myoglobin removal in clinical conditions such as liver disease and trauma, respectively, and for ticagrelor and rivaroxaban removal in cardiothoracic surgery procedures. CytoSorb has also received FDA Emergency Use Authorization in the United States for use in adult critically ill COVID-19 patients with impending or confirmed respiratory failure. CytoSorb is not yet approved or cleared in the
In the U.S. and Canada, CytoSorbents is developing the DrugSorb™-ATR antithrombotic removal system, an investigational device based on an equivalent polymer technology to CytoSorb, to reduce the severity of perioperative bleeding in high-risk surgery due to blood thinning drugs. It has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of the direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the
The Company has numerous marketed products and products under development based upon this unique blood purification technology protected by many issued U.S. and international patents and registered trademarks, and multiple patent applications pending, including ECOS-300CY®, CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®, K+ontrol™, DrugSorb™, ContrastSorb, and others. For more information, please visit the Company's website at https://ir.cytosorbents.com/ and follow us on Facebook and X and LinkedIn.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, future targets and outlooks for our business, representations and contentions, and the outcome of our regulatory submissions, and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, our restructuring of our direct sales team and strategy in Germany, ability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval, our ability to complete our strategic workforce and cost reduction plan to reduce costs, optimize operations, and achieve cash-flow break-even in the first quarter of 2026, our ability to appropriately finance the Company, and the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2025, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow Us on Facebook and X
Peter J. Mariani, Chief Financial Officer
305 College Road East
pmariani@cytosorbents.com
Investor Relations Contact:
Aman Patel, CFA & Adanna G. Alexander, PhD
ICR Healthcare
ir@cytosorbents.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-participate-in-a-virtual-fireside-chat-with-d-boral-capital-on-monday-december-15-2025-302637393.html
SOURCE Cytosorbents Corp
FAQ
Who will represent CytoSorbents (CTSO) in the December 15, 2025 fireside chat?
What key financial metric will CytoSorbents (CTSO) discuss during the December 15, 2025 event?
When is a regulatory decision for DrugSorb-ATR expected for CytoSorbents (CTSO)?
What is the date and time of the CytoSorbents (CTSO) virtual fireside chat with D. Boral Capital?
How can investors register for the CytoSorbents (CTSO) December 15, 2025 fireside chat?
